Daily Cosmetic Research Analysis
Analyzed 20 papers and selected 3 impactful papers.
Summary
Analyzed 20 papers and selected 3 impactful articles.
Selected Articles
1. Feasibility and safety of repeat breast-conserving surgery with intraoperative irradiation for local breast carcinoma recurrences: A phase 2 trial.
In a multicenter, prospective phase II trial of selected patients with late in-breast recurrence, repeat breast-conserving surgery with intraoperative focal reirradiation achieved a 90.6% rate of no grade ≥2 fibrosis at 12 months, with durable local control and high mastectomy-free survival up to 60 months. These data support a one-day treatment alternative to salvage mastectomy for carefully selected cases.
Impact: This prospective, registered multicenter trial addresses a high-stakes decision—repeat conservation versus salvage mastectomy—using long follow-up and clinically meaningful toxicity and control endpoints.
Clinical Implications: For ER-positive, node-negative, small, late in-breast recurrences after prior whole-breast RT, a one-day repeat BCS with IOReIrr can be discussed as a safe, cosmetically favorable alternative to salvage mastectomy within shared decision-making.
Key Findings
- 90.6% (48/53) had no grade ≥2 breast fibrosis at 12 months after BCS + IOReIrr (95% CI: 79.3–96.9).
- Local recurrence-free survival was 96.8% at 36 months and 81.2% at 60 months.
- Mastectomy-free rates were 94.2% at 36 months and 92.3% at 60 months.
- Only three new local relapses occurred after the second BCS + IOReIrr during median 59-month follow-up.
Methodological Strengths
- Prospective, multicenter design with trial registration (NCT02386371)
- Long median follow-up (59 months) with standardized toxicity (CTCAE v4.0) and time-to-event endpoints
Limitations
- Single-arm design without a concurrent control arm limits causal inference
- Restricted to selected low-risk recurrences; generalizability may be limited
Future Directions: Randomized comparisons against salvage mastectomy or external-beam reirradiation, integration with modern systemic therapies, and patient-reported outcomes focusing on cosmesis and quality of life.
BACKGROUND AND PURPOSE: The RE-IORT prospective, multicenter, single-arm phase II trial (NCT02386371) evaluated the feasibility and safety of repeat breast-conserving surgery (BCS) combined with focal reirradiation using intraoperative radiotherapy (IOReIrr) in patients with locally recurrent breast carcinoma. PATIENTS AND METHODS: Eligible patients had in-breast recurrence ≥ 5 years after whole-breast radiotherapy, with low-risk features (unifocal T1N0, non-lobular histology, grade 1-2, estrogen receptor-positive, HER2-negative). The primary endpoint was the absence of grade ≥ 2 breast fibrosis at month 12 post-BCS + IOReIrr, reported using the Common Terminology Criteria for Adverse Events, version 4.0. Secondary endpoints were cumulative incidence of local relapse, local relapse-free/distant metastasis-free/disease-free/overall/mastectomy-free survival, quality of life, definitive cosmetic results and satisfaction.
2. A photocuring double-network hydrogel enhances mechanotransduction and scavenges ROS to accelerate pressure injury healing.
A glucose-responsive, photocured PAHN–SilMA double-network hydrogel that stiffens 45-fold in high-glucose conditions and scavenges ROS via cyanidin chloride accelerated closure and neovascularization of hyperglycemic pressure injuries. Benefits were mechanistically linked to synergistic activation of TRPV4–CaMKII-mediated mechanotransduction and oxidative stress mitigation.
Impact: Introduces a mechanistically rational, environment-responsive biomaterial that couples adaptive mechanics with redox regulation, demonstrating efficacy and pathway-level insight in a disease-relevant in vivo model.
Clinical Implications: While preclinical, the design principle of glucose-triggered stiffening plus ROS scavenging could inform next-generation dressings for chronic diabetic pressure injuries, with potential to improve healing quality and scarring.
Key Findings
- Photocured PAHN–SilMA hydrogel undergoes glucose-responsive secondary polymerization, increasing storage modulus 45-fold in high-glucose conditions.
- In a hyperglycemic pressure injury model, the hydrogel accelerated wound closure and enhanced neovascularization versus control.
- Cyanidin chloride imparted robust ROS scavenging, synergizing with mechanical reinforcement.
- Therapeutic effects were mediated via activation of the TRPV4–CaMKII mechanotransduction axis and oxidative stress mitigation.
Methodological Strengths
- Disease-relevant in vivo model with quantitative biomechanics and histologic vascularization metrics
- Mechanistic validation linking outcomes to TRPV4–CaMKII signaling and redox modulation
Limitations
- Preclinical animal study; human safety and efficacy remain untested
- Short-term evaluation; long-term remodeling, durability, and infection risk not assessed
Future Directions: Scale-up manufacturing, biocompatibility/toxicology profiling, and early-phase clinical trials in diabetic pressure injuries; exploration of tunable stiffness-redox couplings for other chronic wounds.
Diabetic pressure injuries represent a significant clinical challenge, characterized by impaired mechanotransduction and excessive oxidative stress. To address these issues, we developed a double-network hydrogel composed of poly (acrylic acid-co-hydroxyethyl methacrylate-co-N-hydroxysuccinimide ester) (PAHN) and methacrylated silk fibroin (SilMA). This hydrogel featured a unique glucose-responsive secondary polymerization following initial photocuring, enabling autonomous matrix reinforcement in the hyperglycemic wound environment. The material demonstrated a 45-fold increase in storage modulus under high-glucose conditions, providing adaptive mechanical support. Incorporated cyanidin chloride (CC) conferred potent reactive oxygen species (ROS) scavenging capacity. In a hyperglycemic pressure injury model, the hydrogel significantly accelerated wound closure and enhanced neovascularization. Mechanistic studies revealed that these therapeutic benefits were mediated through synergistic activation of the TRPV4-CaMKII mechanotransduction axis and effective mitigation of oxidative stress. This work presented a promising strategy for treating complex chronic wounds by integrating dynamic mechanical reinforcement with targeted biochemical regulation.
3. Gland-preserving surgery versus total gland excision for benign submandibular tumors: A systematic review and meta-analysis.
Across four studies (n=318), gland-preserving surgery improved unstimulated salivary flow at 6 and 12 months, reduced operative time and blood loss, and lowered marginal mandibular nerve injury risk, with superior facial contour and no increase in recurrence versus total excision. Findings support SGPS as a safe, function- and appearance-preserving option for benign SMG tumors.
Impact: Provides synthesized comparative evidence favoring gland preservation on function, nerve safety, and cosmesis without oncologic compromise, informing surgical decision-making.
Clinical Implications: For appropriately selected benign SMG tumors, SGPS should be considered to preserve salivary function and facial contour while minimizing marginal mandibular nerve injury risk, without increasing recurrence.
Key Findings
- Unstimulated saliva flow favored SGPS at 6 months (MD 0.32 mL/min; 95% CI 0.23–0.41) and 12 months (MD 0.24 mL/min; 95% CI 0.10–0.38).
- SGPS reduced operative time (MD −10.58 min; 95% CI −14.61 to −6.56) and blood loss (MD −15.43 mL; 95% CI −30.82 to −0.04).
- Lower risk of marginal mandibular nerve injury with SGPS (RD −0.09; 95% CI −0.16 to −0.03).
- No significant differences in stimulated saliva flow, recurrence, or other complications; facial contour outcomes favored SGPS (SMD 1.95; 95% CI 0.20–3.70).
Methodological Strengths
- Systematic search across multiple databases with meta-analytic pooling
- Multiple clinically relevant endpoints including function, nerve injury, and facial contour
Limitations
- Only four studies with 318 patients; potential heterogeneity and risk of bias
- Cosmetic outcomes and salivary function measures may vary across studies
Future Directions: Prospective comparative trials with standardized functional and aesthetic outcome measures and long-term follow-up to confirm durability and safety.
BACKGROUND: Preservation of gland function is gaining importance in the surgical management of benign submandibular gland (SMG) tumors, yet comparative evidence between gland-preserving and total excision approaches remains limited. This study aimed to compare functional, oncologic and cosmetic outcomes between submandibular gland-preserving surgery (SGPS) and total submandibular gland excision (SGTE) for benign SMG tumors. METHODS: A systematic review and meta-analysis were conducted using studies retrieved from PubMed, Embase, and the Cochrane Library. The primary outcome was postoperative salivary gland function. Secondary outcomes included operative duration, intraoperative blood loss, tumor recurrence, postoperative complications, and facial contour outcomes. RESULTS: Four studies involving a total of 318 patients were included. SGPS demonstrated better preservation of unstimulated saliva flow at six months (MD, 0.32 mL/min; 95% CI, 0.23 to 0.41) and twelve months (MD, 0.24 mL/min; 95% CI, 0.10 to 0.38). Compared with SGTE, SGPS was also associated with shorter operative duration (mean difference [MD], -10.58 min; 95% confidence interval [CI], -14.61 to -6.56), reduced intraoperative blood loss (MD, -15.43 mL; 95% CI, -30.82 to -0.04), and lower risk of marginal mandibular nerve injury (risk difference [RD], -0.09; 95% CI, -0.16 to -0.03). No significant differences were observed in stimulated saliva flow, recurrence, or other complications. Facial contour outcomes significantly favored SGPS (standardized mean difference [SMD], 1.95; 95% CI, 0.20 to 3.70). CONCLUSION: SGPS offers functional and cosmetic advantages over SGTE without compromising oncologic safety, supporting its role as a safe and effective alternative for appropriately selected patients with benign SMG tumors.